Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
19.34
+0.68 (3.64%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States.
The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Paul A. Wagner |
Contact Details
Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States | |
| Phone | 310 618 6994 |
| Website | fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419041 |
| CUSIP Number | 34962G109 |
| ISIN Number | US34962G1094 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President and Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician and Director |
| Christopher Roenfeldt | Chief Operating Officer |
| Steven Ruhl | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 424B3 | Prospectus |
| Dec 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 3, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 20, 2024 | 8-K | Current Report |